Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Idiopathic Pulmonary Fibrosis | 67 | 2025 | 113 | 12.540 |
Why?
|
Lung Diseases, Interstitial | 58 | 2025 | 149 | 11.040 |
Why?
|
Pulmonary Fibrosis | 44 | 2025 | 109 | 10.290 |
Why?
|
Lung | 87 | 2025 | 1487 | 5.550 |
Why?
|
Arthritis, Rheumatoid | 23 | 2024 | 261 | 4.980 |
Why?
|
Syndecan-2 | 6 | 2022 | 14 | 2.760 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 23 | 2024 | 604 | 2.400 |
Why?
|
Lung Injury | 8 | 2024 | 121 | 2.270 |
Why?
|
Tomography, X-Ray Computed | 39 | 2025 | 2091 | 2.190 |
Why?
|
Bleomycin | 22 | 2024 | 154 | 1.980 |
Why?
|
Fibroblasts | 24 | 2025 | 887 | 1.910 |
Why?
|
Lung Transplantation | 18 | 2023 | 314 | 1.840 |
Why?
|
Pulmonary Emphysema | 12 | 2023 | 93 | 1.770 |
Why?
|
Biomarkers | 31 | 2025 | 3103 | 1.590 |
Why?
|
Lymphangioleiomyomatosis | 10 | 2023 | 16 | 1.550 |
Why?
|
Smoking | 20 | 2024 | 1049 | 1.450 |
Why?
|
Humans | 205 | 2025 | 125438 | 1.340 |
Why?
|
Single-Cell Analysis | 7 | 2024 | 288 | 1.310 |
Why?
|
Indoles | 5 | 2025 | 191 | 1.310 |
Why?
|
Lung Diseases | 10 | 2025 | 384 | 1.310 |
Why?
|
Alveolar Epithelial Cells | 8 | 2025 | 34 | 1.260 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2022 | 509 | 1.230 |
Why?
|
Radiation Injuries | 2 | 2022 | 143 | 1.230 |
Why?
|
Mucin-5B | 10 | 2024 | 12 | 1.140 |
Why?
|
Receptors, Interleukin-6 | 2 | 2021 | 42 | 0.890 |
Why?
|
Mice | 53 | 2025 | 17744 | 0.890 |
Why?
|
Vital Capacity | 8 | 2024 | 75 | 0.880 |
Why?
|
Animals | 65 | 2025 | 34309 | 0.880 |
Why?
|
Transforming Growth Factor beta1 | 6 | 2024 | 129 | 0.880 |
Why?
|
Disease Progression | 16 | 2024 | 2083 | 0.870 |
Why?
|
Silicosis | 1 | 2023 | 4 | 0.850 |
Why?
|
Middle Aged | 71 | 2025 | 26827 | 0.840 |
Why?
|
Pyridones | 4 | 2023 | 118 | 0.830 |
Why?
|
MicroRNAs | 6 | 2025 | 855 | 0.810 |
Why?
|
Tobacco Smoke Pollution | 3 | 2013 | 77 | 0.810 |
Why?
|
Primary Graft Dysfunction | 5 | 2023 | 24 | 0.810 |
Why?
|
Telomere | 7 | 2024 | 220 | 0.800 |
Why?
|
Aged | 57 | 2025 | 19739 | 0.800 |
Why?
|
Male | 94 | 2025 | 61626 | 0.800 |
Why?
|
Idiopathic Interstitial Pneumonias | 3 | 2024 | 8 | 0.780 |
Why?
|
Cryopreservation | 2 | 2020 | 72 | 0.770 |
Why?
|
Endothelial Cells | 11 | 2023 | 501 | 0.770 |
Why?
|
Endoplasmic Reticulum Stress | 2 | 2019 | 120 | 0.770 |
Why?
|
Gene Expression Profiling | 12 | 2024 | 1756 | 0.760 |
Why?
|
Mice, Inbred C57BL | 24 | 2025 | 4420 | 0.760 |
Why?
|
Carbon Monoxide | 3 | 2019 | 29 | 0.760 |
Why?
|
Female | 97 | 2025 | 66887 | 0.750 |
Why?
|
Antimetabolites | 1 | 2021 | 33 | 0.740 |
Why?
|
Pulmonologists | 2 | 2021 | 4 | 0.720 |
Why?
|
Proteomics | 8 | 2025 | 507 | 0.700 |
Why?
|
Forced Expiratory Volume | 6 | 2018 | 171 | 0.690 |
Why?
|
Respiratory Function Tests | 15 | 2021 | 198 | 0.680 |
Why?
|
Matrix Metalloproteinase 7 | 4 | 2016 | 21 | 0.670 |
Why?
|
Emphysema | 4 | 2023 | 67 | 0.670 |
Why?
|
Fibrosis | 10 | 2024 | 441 | 0.660 |
Why?
|
Lung Neoplasms | 6 | 2023 | 1654 | 0.660 |
Why?
|
Palmitic Acid | 1 | 2019 | 34 | 0.660 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 51 | 0.650 |
Why?
|
Hospitalization | 2 | 2025 | 1792 | 0.630 |
Why?
|
Hyaluronic Acid | 5 | 2021 | 96 | 0.620 |
Why?
|
Epithelial Cells | 9 | 2023 | 909 | 0.610 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2022 | 339 | 0.600 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2016 | 113 | 0.600 |
Why?
|
Diet, High-Fat | 1 | 2019 | 210 | 0.580 |
Why?
|
Scleroderma, Systemic | 4 | 2024 | 118 | 0.580 |
Why?
|
Macrophages, Alveolar | 4 | 2020 | 49 | 0.560 |
Why?
|
Smoke | 2 | 2016 | 61 | 0.540 |
Why?
|
Inflammasomes | 2 | 2016 | 150 | 0.540 |
Why?
|
Antiviral Agents | 2 | 2021 | 767 | 0.540 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 304 | 0.540 |
Why?
|
Critical Illness | 1 | 2021 | 601 | 0.530 |
Why?
|
Hermanski-Pudlak Syndrome | 5 | 2022 | 8 | 0.530 |
Why?
|
Autophagy | 6 | 2023 | 393 | 0.530 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 3 | 2022 | 10 | 0.530 |
Why?
|
Aging | 3 | 2024 | 1182 | 0.520 |
Why?
|
Enzyme Inhibitors | 3 | 2018 | 587 | 0.520 |
Why?
|
RNA | 1 | 2020 | 574 | 0.520 |
Why?
|
Polymorphism, Genetic | 6 | 2017 | 818 | 0.510 |
Why?
|
Severity of Illness Index | 11 | 2025 | 2912 | 0.510 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 2 | 2024 | 43 | 0.500 |
Why?
|
Sirolimus | 4 | 2019 | 227 | 0.500 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 49 | 0.490 |
Why?
|
Bronchoalveolar Lavage Fluid | 11 | 2021 | 149 | 0.490 |
Why?
|
Pollen | 1 | 2015 | 46 | 0.480 |
Why?
|
Graft Rejection | 6 | 2021 | 586 | 0.480 |
Why?
|
Blood Proteins | 4 | 2025 | 124 | 0.470 |
Why?
|
Adult | 36 | 2025 | 29635 | 0.460 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2022 | 493 | 0.460 |
Why?
|
Protein Kinase Inhibitors | 3 | 2025 | 543 | 0.460 |
Why?
|
Cohort Studies | 19 | 2025 | 4843 | 0.450 |
Why?
|
Transforming Growth Factor beta | 6 | 2022 | 466 | 0.440 |
Why?
|
Pulmonary Alveoli | 8 | 2022 | 134 | 0.440 |
Why?
|
Air Pollutants | 1 | 2015 | 102 | 0.440 |
Why?
|
Signal Transduction | 13 | 2023 | 4595 | 0.430 |
Why?
|
Pericytes | 1 | 2013 | 21 | 0.430 |
Why?
|
Double-Blind Method | 7 | 2025 | 1635 | 0.430 |
Why?
|
Mice, Transgenic | 4 | 2022 | 2414 | 0.430 |
Why?
|
Allergens | 1 | 2015 | 252 | 0.420 |
Why?
|
Smokers | 5 | 2023 | 40 | 0.420 |
Why?
|
Gene Expression Regulation | 9 | 2022 | 2524 | 0.420 |
Why?
|
A549 Cells | 3 | 2024 | 44 | 0.410 |
Why?
|
Genetic Predisposition to Disease | 8 | 2024 | 3175 | 0.410 |
Why?
|
Congresses as Topic | 1 | 2014 | 175 | 0.410 |
Why?
|
Lymphangiogenesis | 4 | 2020 | 18 | 0.410 |
Why?
|
Myofibroblasts | 3 | 2024 | 77 | 0.400 |
Why?
|
Prognosis | 11 | 2023 | 4690 | 0.400 |
Why?
|
Primary Prevention | 1 | 2014 | 172 | 0.400 |
Why?
|
Mitochondria | 6 | 2023 | 679 | 0.400 |
Why?
|
Transcriptome | 4 | 2024 | 977 | 0.400 |
Why?
|
Antibiotics, Antineoplastic | 4 | 2021 | 128 | 0.380 |
Why?
|
Citrullination | 2 | 2022 | 6 | 0.380 |
Why?
|
Sequence Analysis, RNA | 4 | 2024 | 371 | 0.380 |
Why?
|
Hypertension, Pulmonary | 6 | 2020 | 439 | 0.370 |
Why?
|
Respiratory Mucosa | 3 | 2021 | 91 | 0.370 |
Why?
|
Follow-Up Studies | 12 | 2025 | 5174 | 0.360 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 360 | 0.360 |
Why?
|
Aged, 80 and over | 13 | 2025 | 6558 | 0.360 |
Why?
|
Pattern Recognition, Automated | 1 | 2011 | 49 | 0.360 |
Why?
|
Virus Internalization | 2 | 2021 | 55 | 0.360 |
Why?
|
HSP90 Heat-Shock Proteins | 3 | 2016 | 37 | 0.340 |
Why?
|
Cells, Cultured | 10 | 2025 | 3043 | 0.340 |
Why?
|
Intracellular Signaling Peptides and Proteins | 4 | 2019 | 560 | 0.340 |
Why?
|
Cellular Senescence | 3 | 2021 | 163 | 0.340 |
Why?
|
Macrophages | 5 | 2023 | 625 | 0.330 |
Why?
|
Phosphoproteins | 3 | 2018 | 420 | 0.330 |
Why?
|
Vesicular Transport Proteins | 3 | 2020 | 120 | 0.330 |
Why?
|
Trophoblasts | 2 | 2021 | 113 | 0.330 |
Why?
|
Up-Regulation | 6 | 2019 | 875 | 0.330 |
Why?
|
Matrix Metalloproteinase 1 | 2 | 2014 | 24 | 0.330 |
Why?
|
Adaptor Proteins, Signal Transducing | 4 | 2018 | 560 | 0.320 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 3 | 2025 | 9 | 0.320 |
Why?
|
Risk Factors | 16 | 2024 | 10298 | 0.320 |
Why?
|
Matrix Metalloproteinases, Secreted | 2 | 2023 | 4 | 0.310 |
Why?
|
Gene Expression | 2 | 2020 | 1554 | 0.310 |
Why?
|
Immunomodulation | 2 | 2021 | 79 | 0.310 |
Why?
|
Vascular Endothelial Growth Factor D | 4 | 2017 | 6 | 0.300 |
Why?
|
Leukocytes, Mononuclear | 3 | 2019 | 325 | 0.300 |
Why?
|
Autoantibodies | 4 | 2024 | 432 | 0.300 |
Why?
|
Extracellular Matrix Proteins | 4 | 2022 | 156 | 0.300 |
Why?
|
Homeostasis | 6 | 2023 | 704 | 0.290 |
Why?
|
Extracellular Matrix | 3 | 2025 | 238 | 0.290 |
Why?
|
Hydroxychloroquine | 2 | 2018 | 17 | 0.290 |
Why?
|
Protein Processing, Post-Translational | 4 | 2023 | 360 | 0.290 |
Why?
|
Inflammation | 5 | 2021 | 1447 | 0.280 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 2 | 2018 | 7 | 0.280 |
Why?
|
Promoter Regions, Genetic | 7 | 2019 | 1338 | 0.280 |
Why?
|
Transplant Recipients | 3 | 2019 | 217 | 0.270 |
Why?
|
Genetic Testing | 3 | 2021 | 1016 | 0.270 |
Why?
|
Disease Models, Animal | 9 | 2024 | 4406 | 0.270 |
Why?
|
Gene Regulatory Networks | 2 | 2022 | 363 | 0.260 |
Why?
|
In Vitro Techniques | 2 | 2021 | 972 | 0.260 |
Why?
|
Cell Proliferation | 5 | 2024 | 2372 | 0.260 |
Why?
|
Telomerase | 4 | 2020 | 169 | 0.260 |
Why?
|
Cell Differentiation | 5 | 2025 | 1908 | 0.250 |
Why?
|
Immunohistochemistry | 4 | 2020 | 1703 | 0.250 |
Why?
|
Kruppel-Like Transcription Factors | 2 | 2024 | 114 | 0.250 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 6 | 2020 | 824 | 0.250 |
Why?
|
Chronic Disease | 5 | 2021 | 1192 | 0.240 |
Why?
|
TOR Serine-Threonine Kinases | 4 | 2021 | 436 | 0.240 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2019 | 1033 | 0.240 |
Why?
|
Protein Kinases | 2 | 2018 | 331 | 0.240 |
Why?
|
Bronchiolitis Obliterans | 2 | 2017 | 40 | 0.240 |
Why?
|
Stem Cells | 3 | 2021 | 709 | 0.240 |
Why?
|
Prospective Studies | 9 | 2022 | 6174 | 0.240 |
Why?
|
Galectin 3 | 2 | 2016 | 36 | 0.240 |
Why?
|
Treatment Outcome | 11 | 2022 | 12303 | 0.230 |
Why?
|
Apoptosis | 5 | 2019 | 1817 | 0.230 |
Why?
|
Case-Control Studies | 10 | 2021 | 3310 | 0.230 |
Why?
|
Gene Silencing | 3 | 2021 | 241 | 0.230 |
Why?
|
Methylmalonic Acid | 1 | 2024 | 15 | 0.230 |
Why?
|
Antibodies, Viral | 2 | 2023 | 1153 | 0.220 |
Why?
|
United States | 13 | 2024 | 10924 | 0.220 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 126 | 0.220 |
Why?
|
Intensive Care Units | 2 | 2021 | 493 | 0.220 |
Why?
|
Fatigue | 1 | 2025 | 188 | 0.220 |
Why?
|
Precision Medicine | 2 | 2024 | 321 | 0.210 |
Why?
|
Niacin | 1 | 2023 | 58 | 0.210 |
Why?
|
Citrulline | 2 | 2016 | 111 | 0.210 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2016 | 586 | 0.210 |
Why?
|
Cell Movement | 4 | 2024 | 854 | 0.210 |
Why?
|
Immunoglobulin A | 2 | 2023 | 207 | 0.210 |
Why?
|
Genome-Wide Association Study | 3 | 2020 | 1694 | 0.210 |
Why?
|
Sarcoidosis | 1 | 2023 | 60 | 0.210 |
Why?
|
Macular Degeneration | 1 | 2024 | 115 | 0.200 |
Why?
|
Interleukin-1beta | 2 | 2016 | 162 | 0.200 |
Why?
|
Cluster Analysis | 2 | 2022 | 405 | 0.200 |
Why?
|
Hospital Mortality | 2 | 2021 | 1027 | 0.200 |
Why?
|
Pseudomonas Infections | 1 | 2023 | 114 | 0.200 |
Why?
|
Reperfusion Injury | 1 | 2023 | 114 | 0.200 |
Why?
|
Collagen | 2 | 2022 | 317 | 0.200 |
Why?
|
Genomics | 2 | 2024 | 1520 | 0.200 |
Why?
|
Synovial Membrane | 1 | 2022 | 27 | 0.200 |
Why?
|
Mammals | 2 | 2022 | 257 | 0.200 |
Why?
|
Anti-Citrullinated Protein Antibodies | 1 | 2022 | 4 | 0.200 |
Why?
|
Retrospective Studies | 18 | 2024 | 16362 | 0.190 |
Why?
|
beta Catenin | 2 | 2023 | 214 | 0.190 |
Why?
|
Immunosuppressive Agents | 4 | 2023 | 645 | 0.190 |
Why?
|
DNA | 2 | 2018 | 1619 | 0.190 |
Why?
|
Sp1 Transcription Factor | 1 | 2022 | 42 | 0.190 |
Why?
|
Antirheumatic Agents | 2 | 2021 | 120 | 0.190 |
Why?
|
Rituximab | 2 | 2024 | 152 | 0.190 |
Why?
|
Machine Learning | 1 | 2024 | 251 | 0.190 |
Why?
|
Cognitive Dysfunction | 1 | 2025 | 236 | 0.190 |
Why?
|
Elastic Tissue | 1 | 2021 | 19 | 0.190 |
Why?
|
Lymphatic Vessels | 3 | 2019 | 37 | 0.190 |
Why?
|
Chemokine CXCL10 | 3 | 2022 | 53 | 0.190 |
Why?
|
Adenosine Monophosphate | 1 | 2021 | 42 | 0.180 |
Why?
|
Genetic Markers | 4 | 2019 | 605 | 0.180 |
Why?
|
Veterans | 2 | 2023 | 1747 | 0.180 |
Why?
|
Family | 2 | 2025 | 567 | 0.180 |
Why?
|
Respiration, Artificial | 2 | 2022 | 473 | 0.180 |
Why?
|
Immunologic Factors | 2 | 2024 | 173 | 0.180 |
Why?
|
Adaptor Protein Complex 3 | 1 | 2021 | 2 | 0.180 |
Why?
|
Adaptor Protein Complex beta Subunits | 1 | 2021 | 2 | 0.180 |
Why?
|
Primary Cell Culture | 1 | 2021 | 102 | 0.180 |
Why?
|
Respiratory System Abnormalities | 1 | 2021 | 42 | 0.180 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2021 | 86 | 0.180 |
Why?
|
Bronchitis, Chronic | 1 | 2021 | 18 | 0.180 |
Why?
|
Alanine | 1 | 2021 | 187 | 0.180 |
Why?
|
Viral Load | 1 | 2023 | 388 | 0.180 |
Why?
|
Desmoplakins | 1 | 2020 | 10 | 0.180 |
Why?
|
Phenotype | 5 | 2022 | 4269 | 0.180 |
Why?
|
Airway Resistance | 1 | 2020 | 36 | 0.180 |
Why?
|
Vascular Diseases | 1 | 2022 | 155 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 396 | 0.180 |
Why?
|
Extracellular Vesicles | 1 | 2021 | 46 | 0.180 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 1361 | 0.180 |
Why?
|
Acute Lung Injury | 1 | 2021 | 63 | 0.180 |
Why?
|
Administration, Inhalation | 2 | 2019 | 180 | 0.170 |
Why?
|
Mice, SCID | 2 | 2019 | 586 | 0.170 |
Why?
|
Prevalence | 8 | 2024 | 2469 | 0.170 |
Why?
|
Spirometry | 5 | 2021 | 73 | 0.170 |
Why?
|
Celecoxib | 1 | 2020 | 32 | 0.170 |
Why?
|
Epigenesis, Genetic | 1 | 2025 | 702 | 0.170 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2020 | 57 | 0.170 |
Why?
|
Cell Survival | 2 | 2020 | 820 | 0.170 |
Why?
|
Tacrolimus | 1 | 2020 | 97 | 0.170 |
Why?
|
ROC Curve | 3 | 2017 | 572 | 0.170 |
Why?
|
Treatment Failure | 1 | 2021 | 338 | 0.160 |
Why?
|
CD36 Antigens | 1 | 2019 | 37 | 0.160 |
Why?
|
Insulin Resistance | 1 | 2025 | 642 | 0.160 |
Why?
|
DNA Damage | 2 | 2013 | 516 | 0.160 |
Why?
|
Syntenins | 1 | 2019 | 2 | 0.160 |
Why?
|
Longitudinal Studies | 6 | 2020 | 1333 | 0.160 |
Why?
|
Hexosaminidases | 1 | 2019 | 7 | 0.160 |
Why?
|
Infusions, Intravenous | 1 | 2021 | 554 | 0.160 |
Why?
|
Smad7 Protein | 1 | 2019 | 5 | 0.160 |
Why?
|
Polyamines | 1 | 2019 | 28 | 0.160 |
Why?
|
Endostatins | 1 | 2019 | 3 | 0.160 |
Why?
|
Myositis | 2 | 2018 | 61 | 0.160 |
Why?
|
Risk Assessment | 6 | 2017 | 3440 | 0.160 |
Why?
|
Bone Marrow | 3 | 2018 | 322 | 0.160 |
Why?
|
Forkhead Box Protein O3 | 1 | 2019 | 23 | 0.160 |
Why?
|
Tumor Suppressor Proteins | 3 | 2017 | 472 | 0.160 |
Why?
|
Transcription Factor RelA | 1 | 2019 | 55 | 0.160 |
Why?
|
Tissue Donors | 3 | 2017 | 483 | 0.160 |
Why?
|
Disease Susceptibility | 2 | 2021 | 299 | 0.160 |
Why?
|
NF-kappa B | 1 | 2021 | 462 | 0.160 |
Why?
|
Pneumonia | 1 | 2022 | 325 | 0.150 |
Why?
|
Transcriptional Activation | 1 | 2020 | 486 | 0.150 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 253 | 0.150 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 274 | 0.150 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2018 | 17 | 0.150 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2019 | 139 | 0.150 |
Why?
|
Interleukin-8 | 2 | 2022 | 210 | 0.150 |
Why?
|
Collagen Type III | 1 | 2018 | 22 | 0.150 |
Why?
|
Total Lung Capacity | 3 | 2015 | 12 | 0.150 |
Why?
|
Laminin | 1 | 2018 | 69 | 0.150 |
Why?
|
Triglycerides | 1 | 2021 | 576 | 0.150 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 239 | 0.150 |
Why?
|
Cell Line | 6 | 2021 | 2755 | 0.150 |
Why?
|
Biomedical Research | 1 | 2024 | 518 | 0.150 |
Why?
|
Connectome | 1 | 2019 | 104 | 0.150 |
Why?
|
Allografts | 4 | 2021 | 173 | 0.140 |
Why?
|
Carboxyhemoglobin | 1 | 2017 | 10 | 0.140 |
Why?
|
Sensitivity and Specificity | 7 | 2019 | 2057 | 0.140 |
Why?
|
Gain of Function Mutation | 1 | 2018 | 107 | 0.140 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2018 | 24 | 0.140 |
Why?
|
Cystic Fibrosis | 1 | 2020 | 258 | 0.140 |
Why?
|
Survival Rate | 6 | 2019 | 2050 | 0.140 |
Why?
|
Myocytes, Smooth Muscle | 2 | 2016 | 158 | 0.140 |
Why?
|
Mice, Knockout | 4 | 2021 | 3753 | 0.140 |
Why?
|
Fibrinogen | 1 | 2018 | 156 | 0.140 |
Why?
|
Recombinant Proteins | 1 | 2021 | 1400 | 0.140 |
Why?
|
Histocompatibility | 1 | 2017 | 47 | 0.140 |
Why?
|
Thorax | 1 | 2018 | 73 | 0.140 |
Why?
|
rho-Associated Kinases | 1 | 2018 | 53 | 0.140 |
Why?
|
Respiratory Tract Diseases | 1 | 2018 | 75 | 0.140 |
Why?
|
Age Factors | 4 | 2019 | 2828 | 0.140 |
Why?
|
Tuberous Sclerosis | 2 | 2019 | 121 | 0.140 |
Why?
|
Referral and Consultation | 1 | 2021 | 543 | 0.140 |
Why?
|
Metabolic Syndrome | 1 | 2021 | 342 | 0.140 |
Why?
|
Carrier Proteins | 2 | 2013 | 1034 | 0.140 |
Why?
|
Photopheresis | 1 | 2017 | 3 | 0.140 |
Why?
|
Peptide Fragments | 1 | 2021 | 781 | 0.140 |
Why?
|
Isoantibodies | 1 | 2017 | 72 | 0.140 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 625 | 0.140 |
Why?
|
Syk Kinase | 1 | 2017 | 16 | 0.140 |
Why?
|
Parenchymal Tissue | 1 | 2016 | 2 | 0.140 |
Why?
|
Protein-Arginine Deiminases | 3 | 2023 | 6 | 0.140 |
Why?
|
Sepsis | 1 | 2021 | 484 | 0.130 |
Why?
|
Alemtuzumab | 1 | 2017 | 86 | 0.130 |
Why?
|
Regression Analysis | 4 | 2024 | 781 | 0.130 |
Why?
|
Instillation, Drug | 1 | 2016 | 7 | 0.130 |
Why?
|
Microbiota | 1 | 2021 | 387 | 0.130 |
Why?
|
Protein Unfolding | 1 | 2016 | 10 | 0.130 |
Why?
|
Osteopontin | 1 | 2016 | 48 | 0.130 |
Why?
|
Immunoproteins | 1 | 2016 | 2 | 0.130 |
Why?
|
Cell Nucleus | 1 | 2019 | 680 | 0.130 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 178 | 0.130 |
Why?
|
Glucose | 1 | 2021 | 878 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2024 | 2652 | 0.130 |
Why?
|
HLA Antigens | 1 | 2017 | 237 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 27 | 0.130 |
Why?
|
Taste | 1 | 2016 | 32 | 0.130 |
Why?
|
Interleukin-18 | 1 | 2016 | 61 | 0.130 |
Why?
|
Bronchoalveolar Lavage | 2 | 2013 | 22 | 0.130 |
Why?
|
Lymphoproliferative Disorders | 1 | 2017 | 223 | 0.130 |
Why?
|
Cigarette Smoking | 1 | 2016 | 59 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2015 | 9 | 0.130 |
Why?
|
Magnoliopsida | 1 | 2015 | 4 | 0.130 |
Why?
|
Patient Reported Outcome Measures | 1 | 2017 | 173 | 0.120 |
Why?
|
Embolism, Fat | 1 | 2015 | 6 | 0.120 |
Why?
|
B-Cell Activating Factor | 1 | 2015 | 4 | 0.120 |
Why?
|
Urbanization | 1 | 2015 | 7 | 0.120 |
Why?
|
Young Adult | 6 | 2024 | 9085 | 0.120 |
Why?
|
Cities | 1 | 2015 | 47 | 0.120 |
Why?
|
Lymphoid Tissue | 1 | 2015 | 46 | 0.120 |
Why?
|
Sulfur | 1 | 2015 | 13 | 0.120 |
Why?
|
Biological Assay | 1 | 2016 | 104 | 0.120 |
Why?
|
Iron-Sulfur Proteins | 1 | 2015 | 5 | 0.120 |
Why?
|
Transplants | 1 | 2015 | 34 | 0.120 |
Why?
|
Rare Diseases | 1 | 2017 | 190 | 0.120 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2015 | 6 | 0.120 |
Why?
|
Mexico | 1 | 2015 | 182 | 0.120 |
Why?
|
Everolimus | 1 | 2015 | 50 | 0.120 |
Why?
|
Logistic Models | 5 | 2019 | 1808 | 0.120 |
Why?
|
Mass Screening | 1 | 2021 | 785 | 0.120 |
Why?
|
Radiation Pneumonitis | 1 | 2014 | 13 | 0.120 |
Why?
|
Lipids | 1 | 2018 | 522 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 69 | 0.120 |
Why?
|
Radiation Injuries, Experimental | 1 | 2014 | 22 | 0.120 |
Why?
|
Adaptive Immunity | 1 | 2015 | 89 | 0.120 |
Why?
|
Chemokines | 1 | 2015 | 133 | 0.120 |
Why?
|
Phospholipases A2 | 1 | 2014 | 36 | 0.120 |
Why?
|
Temperature | 1 | 2015 | 307 | 0.120 |
Why?
|
Drug Approval | 1 | 2015 | 43 | 0.120 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2017 | 293 | 0.120 |
Why?
|
Epitopes | 1 | 2016 | 433 | 0.120 |
Why?
|
Postoperative Complications | 2 | 2017 | 3055 | 0.110 |
Why?
|
Cysteine-Rich Protein 61 | 1 | 2014 | 5 | 0.110 |
Why?
|
Bronchodilator Agents | 1 | 2016 | 151 | 0.110 |
Why?
|
Herpesvirus 4, Human | 1 | 2017 | 674 | 0.110 |
Why?
|
Sex Factors | 2 | 2015 | 1282 | 0.110 |
Why?
|
Area Under Curve | 1 | 2015 | 318 | 0.110 |
Why?
|
Mononuclear Phagocyte System | 1 | 2014 | 9 | 0.110 |
Why?
|
Matrix Metalloproteinase 8 | 1 | 2014 | 15 | 0.110 |
Why?
|
Protein Structure, Tertiary | 1 | 2016 | 767 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 150 | 0.110 |
Why?
|
Linear Models | 4 | 2019 | 687 | 0.110 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 1899 | 0.110 |
Why?
|
Reproducibility of Results | 4 | 2017 | 2904 | 0.110 |
Why?
|
Radiotherapy | 1 | 2014 | 138 | 0.110 |
Why?
|
Genetic Variation | 1 | 2020 | 1505 | 0.110 |
Why?
|
Seasons | 1 | 2015 | 312 | 0.110 |
Why?
|
Hydroxyproline | 1 | 2013 | 7 | 0.110 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 88 | 0.110 |
Why?
|
Adipocytes | 1 | 2014 | 141 | 0.110 |
Why?
|
Cause of Death | 1 | 2016 | 472 | 0.110 |
Why?
|
Caveolin 1 | 1 | 2013 | 48 | 0.110 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2016 | 296 | 0.110 |
Why?
|
Asthma | 1 | 2021 | 756 | 0.110 |
Why?
|
Hypoxia | 1 | 2015 | 248 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 634 | 0.110 |
Why?
|
Glucose Transporter Type 1 | 1 | 2013 | 24 | 0.110 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 137 | 0.110 |
Why?
|
Circadian Rhythm | 1 | 2015 | 276 | 0.110 |
Why?
|
Survival Analysis | 2 | 2019 | 1494 | 0.100 |
Why?
|
Transplantation | 1 | 2013 | 27 | 0.100 |
Why?
|
Antibodies | 1 | 2014 | 374 | 0.100 |
Why?
|
Patient Readmission | 1 | 2016 | 385 | 0.100 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2012 | 18 | 0.100 |
Why?
|
DNA, Mitochondrial | 1 | 2013 | 211 | 0.100 |
Why?
|
B-Lymphocytes | 1 | 2015 | 532 | 0.100 |
Why?
|
Autoantigens | 1 | 2013 | 118 | 0.100 |
Why?
|
Mutation | 6 | 2017 | 5903 | 0.100 |
Why?
|
Pancytopenia | 1 | 2012 | 41 | 0.100 |
Why?
|
Biopsy | 3 | 2015 | 1243 | 0.100 |
Why?
|
Incidence | 5 | 2019 | 3135 | 0.100 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2012 | 55 | 0.090 |
Why?
|
Cyclooxygenase 2 | 1 | 2012 | 155 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 1980 | 0.090 |
Why?
|
Biopsy, Needle | 1 | 2012 | 228 | 0.090 |
Why?
|
Radiographic Image Enhancement | 1 | 2011 | 42 | 0.090 |
Why?
|
Exercise Tolerance | 1 | 2012 | 84 | 0.090 |
Why?
|
HLA-DR Antigens | 1 | 2011 | 77 | 0.090 |
Why?
|
Time Factors | 5 | 2021 | 6324 | 0.090 |
Why?
|
Genotype | 4 | 2018 | 2569 | 0.090 |
Why?
|
Telomere Shortening | 2 | 2024 | 33 | 0.090 |
Why?
|
RNA, Long Noncoding | 1 | 2013 | 217 | 0.090 |
Why?
|
Organ Specificity | 2 | 2021 | 426 | 0.080 |
Why?
|
Protein Binding | 3 | 2020 | 1755 | 0.080 |
Why?
|
Odds Ratio | 3 | 2018 | 1253 | 0.080 |
Why?
|
Antibodies, Antinuclear | 1 | 2009 | 28 | 0.080 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2009 | 43 | 0.080 |
Why?
|
Interleukin-17 | 1 | 2010 | 120 | 0.080 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2022 | 45 | 0.080 |
Why?
|
Syndecan-1 | 1 | 2008 | 7 | 0.080 |
Why?
|
Enzyme Activation | 2 | 2024 | 626 | 0.080 |
Why?
|
Biomarkers, Tumor | 1 | 2017 | 1534 | 0.080 |
Why?
|
Radiography, Thoracic | 1 | 2009 | 151 | 0.080 |
Why?
|
Iceland | 2 | 2019 | 11 | 0.080 |
Why?
|
Clinical Enzyme Tests | 1 | 2008 | 16 | 0.070 |
Why?
|
Methotrexate | 2 | 2021 | 336 | 0.070 |
Why?
|
Liver | 1 | 2015 | 1749 | 0.070 |
Why?
|
Oxidative Stress | 2 | 2014 | 818 | 0.070 |
Why?
|
Peptides | 2 | 2024 | 812 | 0.070 |
Why?
|
Proteins | 2 | 2023 | 1039 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2019 | 670 | 0.070 |
Why?
|
RNA Stability | 1 | 2007 | 84 | 0.070 |
Why?
|
Attitude of Health Personnel | 1 | 2012 | 675 | 0.060 |
Why?
|
Pulmonary Artery | 2 | 2021 | 438 | 0.060 |
Why?
|
Interferon-gamma | 2 | 2023 | 505 | 0.060 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 1714 | 0.060 |
Why?
|
Surveys and Questionnaires | 3 | 2021 | 3743 | 0.060 |
Why?
|
Practice Patterns, Physicians' | 1 | 2012 | 732 | 0.060 |
Why?
|
Microarray Analysis | 1 | 2006 | 237 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2019 | 1430 | 0.060 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2025 | 5 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2014 | 2812 | 0.060 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2025 | 27 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 887 | 0.060 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 63 | 0.060 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 664 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 2007 | 700 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 408 | 0.060 |
Why?
|
Monocytes | 2 | 2023 | 345 | 0.060 |
Why?
|
Basigin | 1 | 2024 | 14 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 730 | 0.060 |
Why?
|
Acetylation | 1 | 2025 | 168 | 0.060 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2024 | 49 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2025 | 275 | 0.060 |
Why?
|
Lakes | 1 | 2024 | 3 | 0.060 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2024 | 97 | 0.060 |
Why?
|
Stress Fibers | 1 | 2023 | 4 | 0.060 |
Why?
|
Neutrophils | 2 | 2021 | 381 | 0.050 |
Why?
|
Acetate-CoA Ligase | 1 | 2023 | 4 | 0.050 |
Why?
|
Reactive Oxygen Species | 2 | 2018 | 495 | 0.050 |
Why?
|
Acetyl Coenzyme A | 1 | 2023 | 13 | 0.050 |
Why?
|
Niacinamide | 1 | 2023 | 23 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2025 | 208 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 1692 | 0.050 |
Why?
|
Acute Disease | 2 | 2018 | 1096 | 0.050 |
Why?
|
Protein Isoforms | 2 | 2016 | 404 | 0.050 |
Why?
|
Mass Spectrometry | 2 | 2016 | 335 | 0.050 |
Why?
|
Pedigree | 2 | 2021 | 1609 | 0.050 |
Why?
|
Thyroid Hormones | 1 | 2023 | 68 | 0.050 |
Why?
|
Professional Practice Gaps | 1 | 2023 | 15 | 0.050 |
Why?
|
Chaperonin Containing TCP-1 | 1 | 2023 | 9 | 0.050 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2024 | 145 | 0.050 |
Why?
|
Plasma Exchange | 1 | 2024 | 84 | 0.050 |
Why?
|
Fenbendazole | 1 | 2022 | 2 | 0.050 |
Why?
|
Fatal Outcome | 2 | 2015 | 357 | 0.050 |
Why?
|
Immunoglobulin M | 1 | 2023 | 212 | 0.050 |
Why?
|
Pyridines | 1 | 2024 | 235 | 0.050 |
Why?
|
Activating Transcription Factor 4 | 1 | 2022 | 34 | 0.050 |
Why?
|
Registries | 2 | 2020 | 1434 | 0.050 |
Why?
|
Actins | 1 | 2025 | 345 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2023 | 49 | 0.050 |
Why?
|
Ubiquitination | 1 | 2023 | 170 | 0.050 |
Why?
|
Nonmuscle Myosin Type IIB | 1 | 2022 | 3 | 0.050 |
Why?
|
Albinism | 1 | 2022 | 8 | 0.050 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2015 | 256 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2022 | 21 | 0.050 |
Why?
|
Hemorrhagic Disorders | 1 | 2022 | 17 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2022 | 53 | 0.050 |
Why?
|
src-Family Kinases | 1 | 2022 | 91 | 0.050 |
Why?
|
Organoids | 1 | 2025 | 281 | 0.050 |
Why?
|
Losartan | 1 | 2022 | 36 | 0.050 |
Why?
|
Adolescent | 2 | 2017 | 19447 | 0.050 |
Why?
|
Regeneration | 1 | 2024 | 211 | 0.050 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 54 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 91 | 0.050 |
Why?
|
Hemiterpenes | 1 | 2001 | 2 | 0.050 |
Why?
|
Molecular Epidemiology | 1 | 2022 | 155 | 0.050 |
Why?
|
Microfilament Proteins | 1 | 2023 | 278 | 0.050 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2023 | 216 | 0.050 |
Why?
|
Lung Diseases, Fungal | 1 | 2021 | 32 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2007 | 1705 | 0.050 |
Why?
|
Histones | 1 | 2025 | 542 | 0.050 |
Why?
|
Pyrimidines | 1 | 2024 | 377 | 0.050 |
Why?
|
Skin | 1 | 2024 | 521 | 0.050 |
Why?
|
Ribotyping | 1 | 2021 | 50 | 0.050 |
Why?
|
Cathepsin L | 1 | 2021 | 11 | 0.050 |
Why?
|
Trans-Activators | 2 | 2015 | 801 | 0.050 |
Why?
|
Unfolded Protein Response | 1 | 2021 | 62 | 0.050 |
Why?
|
Paracrine Communication | 1 | 2021 | 69 | 0.050 |
Why?
|
Capillaries | 1 | 2021 | 63 | 0.050 |
Why?
|
Radiologists | 1 | 2021 | 45 | 0.040 |
Why?
|
Microcirculation | 1 | 2021 | 96 | 0.040 |
Why?
|
Cell Polarity | 1 | 2021 | 121 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2021 | 91 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2021 | 101 | 0.040 |
Why?
|
Stromal Cells | 1 | 2022 | 302 | 0.040 |
Why?
|
Phagocytosis | 1 | 2021 | 171 | 0.040 |
Why?
|
Early Diagnosis | 1 | 2021 | 183 | 0.040 |
Why?
|
Dysbiosis | 1 | 2021 | 122 | 0.040 |
Why?
|
Respiratory System | 1 | 2021 | 97 | 0.040 |
Why?
|
Inflammation Mediators | 1 | 2022 | 245 | 0.040 |
Why?
|
NFATC Transcription Factors | 1 | 2020 | 43 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 2021 | 442 | 0.040 |
Why?
|
Immunity | 1 | 2021 | 192 | 0.040 |
Why?
|
Activins | 1 | 2020 | 73 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2025 | 1119 | 0.040 |
Why?
|
Respiration Disorders | 1 | 2020 | 32 | 0.040 |
Why?
|
Demography | 1 | 2021 | 239 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2021 | 181 | 0.040 |
Why?
|
TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2021 | 262 | 0.040 |
Why?
|
beta Karyopherins | 1 | 2019 | 12 | 0.040 |
Why?
|
Calcium-Binding Proteins | 1 | 2021 | 326 | 0.040 |
Why?
|
Contraindications | 1 | 2000 | 78 | 0.040 |
Why?
|
Software | 1 | 2024 | 687 | 0.040 |
Why?
|
Semaphorins | 1 | 2019 | 29 | 0.040 |
Why?
|
Extracellular Space | 1 | 2019 | 87 | 0.040 |
Why?
|
Zebrafish | 1 | 2022 | 380 | 0.040 |
Why?
|
Lipopolysaccharides | 1 | 2021 | 297 | 0.040 |
Why?
|
Biological Transport | 1 | 2020 | 355 | 0.040 |
Why?
|
Alleles | 2 | 2017 | 1617 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2022 | 779 | 0.040 |
Why?
|
Medicare | 1 | 2023 | 428 | 0.040 |
Why?
|
Cell Separation | 1 | 2020 | 230 | 0.040 |
Why?
|
Maleimides | 1 | 2019 | 11 | 0.040 |
Why?
|
Consensus | 1 | 2023 | 644 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2021 | 295 | 0.040 |
Why?
|
Pulmonary Veins | 1 | 2021 | 161 | 0.040 |
Why?
|
Oxygen | 1 | 2023 | 556 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2019 | 107 | 0.040 |
Why?
|
Glycogen Synthase Kinase 3 beta | 1 | 2019 | 58 | 0.040 |
Why?
|
Species Specificity | 1 | 2019 | 551 | 0.040 |
Why?
|
Microvessels | 1 | 2019 | 57 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2020 | 387 | 0.040 |
Why?
|
Genes | 1 | 2019 | 447 | 0.040 |
Why?
|
Protein Stability | 1 | 2019 | 161 | 0.040 |
Why?
|
Remission Induction | 1 | 2019 | 292 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2020 | 309 | 0.040 |
Why?
|
Databases, Genetic | 1 | 2021 | 475 | 0.040 |
Why?
|
Airway Remodeling | 1 | 2018 | 21 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2021 | 372 | 0.040 |
Why?
|
Smad2 Protein | 1 | 2018 | 50 | 0.040 |
Why?
|
Down-Regulation | 2 | 2014 | 691 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2018 | 64 | 0.040 |
Why?
|
Hospitals, Veterans | 1 | 2020 | 357 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2020 | 364 | 0.040 |
Why?
|
Ligands | 1 | 2019 | 538 | 0.040 |
Why?
|
Mice, Inbred Strains | 1 | 2018 | 309 | 0.040 |
Why?
|
Smad3 Protein | 1 | 2018 | 58 | 0.040 |
Why?
|
Systems Biology | 1 | 2018 | 58 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2019 | 381 | 0.040 |
Why?
|
Genetic Loci | 1 | 2019 | 342 | 0.040 |
Why?
|
Virus Replication | 1 | 2021 | 607 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2022 | 826 | 0.040 |
Why?
|
Patient Discharge | 1 | 2022 | 497 | 0.040 |
Why?
|
Cell Culture Techniques | 1 | 2019 | 276 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2020 | 802 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2017 | 39 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 1077 | 0.040 |
Why?
|
Receptors, Cell Surface | 1 | 2019 | 477 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2017 | 143 | 0.030 |
Why?
|
Walk Test | 1 | 2017 | 24 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 171 | 0.030 |
Why?
|
Mucositis | 1 | 2017 | 19 | 0.030 |
Why?
|
Boston | 1 | 2017 | 109 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 343 | 0.030 |
Why?
|
Transplantation, Homologous | 2 | 2013 | 621 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 1026 | 0.030 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2021 | 1006 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2019 | 384 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 123 | 0.030 |
Why?
|
Muscle Relaxation | 1 | 2016 | 16 | 0.030 |
Why?
|
Phagocytes | 1 | 2016 | 23 | 0.030 |
Why?
|
Computational Biology | 1 | 2021 | 819 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2021 | 765 | 0.030 |
Why?
|
Massachusetts | 1 | 2016 | 125 | 0.030 |
Why?
|
Headache | 1 | 2017 | 107 | 0.030 |
Why?
|
Hydrolases | 1 | 2016 | 56 | 0.030 |
Why?
|
Length of Stay | 1 | 2022 | 1313 | 0.030 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2015 | 9 | 0.030 |
Why?
|
Observer Variation | 1 | 2017 | 300 | 0.030 |
Why?
|
Benzylamines | 1 | 2015 | 15 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2000 | 338 | 0.030 |
Why?
|
Benzoates | 1 | 2015 | 21 | 0.030 |
Why?
|
Molecular Dynamics Simulation | 1 | 2016 | 105 | 0.030 |
Why?
|
Membrane Proteins | 2 | 2014 | 1538 | 0.030 |
Why?
|
Muscle Contraction | 1 | 2016 | 188 | 0.030 |
Why?
|
Molecular Weight | 1 | 2015 | 387 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2000 | 485 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2015 | 69 | 0.030 |
Why?
|
Postoperative Period | 1 | 2016 | 335 | 0.030 |
Why?
|
Transcription Factors | 2 | 2015 | 2603 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2015 | 101 | 0.030 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2015 | 48 | 0.030 |
Why?
|
Serpin E2 | 1 | 2014 | 1 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2018 | 1242 | 0.030 |
Why?
|
Phosphorylation | 1 | 2019 | 1638 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2015 | 163 | 0.030 |
Why?
|
Heart Diseases | 1 | 2000 | 496 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 2015 | 192 | 0.030 |
Why?
|
Angiomyolipoma | 1 | 2014 | 4 | 0.030 |
Why?
|
Prednisone | 1 | 2015 | 278 | 0.030 |
Why?
|
Diarrhea | 1 | 2017 | 317 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2014 | 66 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2014 | 42 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 1173 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2014 | 92 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2015 | 283 | 0.030 |
Why?
|
Pandemics | 1 | 2022 | 1113 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2018 | 465 | 0.030 |
Why?
|
Fibrinolysin | 1 | 2014 | 12 | 0.030 |
Why?
|
Integrin alpha Chains | 1 | 2014 | 15 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 259 | 0.030 |
Why?
|
Mechanotransduction, Cellular | 1 | 2014 | 60 | 0.030 |
Why?
|
Membrane Transport Proteins | 1 | 2015 | 174 | 0.030 |
Why?
|
Calcium Signaling | 1 | 2016 | 244 | 0.030 |
Why?
|
Lymphocytes | 1 | 2016 | 408 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2014 | 126 | 0.030 |
Why?
|
Epitope Mapping | 1 | 2014 | 80 | 0.030 |
Why?
|
Cell Death | 1 | 2015 | 240 | 0.030 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2015 | 231 | 0.030 |
Why?
|
China | 1 | 2015 | 246 | 0.030 |
Why?
|
Galectins | 1 | 2014 | 22 | 0.030 |
Why?
|
Neutrophil Infiltration | 1 | 2014 | 64 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 299 | 0.030 |
Why?
|
Antibody Specificity | 1 | 2014 | 204 | 0.030 |
Why?
|
Mucin-1 | 1 | 2014 | 35 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 914 | 0.030 |
Why?
|
Arginine | 1 | 2016 | 335 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2017 | 780 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 730 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 367 | 0.030 |
Why?
|
Radiography | 1 | 2016 | 809 | 0.030 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2014 | 107 | 0.030 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2013 | 2 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 1240 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 700 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 1001 | 0.030 |
Why?
|
Glycoproteins | 1 | 2015 | 367 | 0.030 |
Why?
|
Leukocytes | 1 | 2014 | 212 | 0.030 |
Why?
|
Laser Capture Microdissection | 1 | 2012 | 7 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 1104 | 0.030 |
Why?
|
Protein Transport | 1 | 2014 | 369 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2013 | 199 | 0.030 |
Why?
|
Sequestosome-1 Protein | 1 | 2012 | 12 | 0.020 |
Why?
|
Beclin-1 | 1 | 2012 | 25 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 168 | 0.020 |
Why?
|
Mice, Neurologic Mutants | 1 | 2012 | 74 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2015 | 556 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 147 | 0.020 |
Why?
|
Fibronectins | 1 | 2012 | 110 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 2429 | 0.020 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2012 | 102 | 0.020 |
Why?
|
Caspase 1 | 1 | 2012 | 43 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2013 | 349 | 0.020 |
Why?
|
Transfection | 1 | 2014 | 1076 | 0.020 |
Why?
|
Rats | 1 | 2018 | 3727 | 0.020 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 166 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2012 | 151 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 227 | 0.020 |
Why?
|
Patient Selection | 1 | 2015 | 697 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 306 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2012 | 210 | 0.020 |
Why?
|
HLA-DRB1 Chains | 1 | 2011 | 38 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 330 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2012 | 246 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2011 | 84 | 0.020 |
Why?
|
Exercise Test | 1 | 2012 | 254 | 0.020 |
Why?
|
Cell Lineage | 1 | 2012 | 350 | 0.020 |
Why?
|
Interleukin-12 Subunit p40 | 1 | 2010 | 14 | 0.020 |
Why?
|
Schistosoma mansoni | 1 | 2010 | 24 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 1065 | 0.020 |
Why?
|
Schistosomiasis mansoni | 1 | 2010 | 24 | 0.020 |
Why?
|
Walking | 1 | 2012 | 216 | 0.020 |
Why?
|
Interleukin-13 | 1 | 2010 | 97 | 0.020 |
Why?
|
Signal Recognition Particle | 1 | 2009 | 9 | 0.020 |
Why?
|
Chemokine CXCL9 | 1 | 2009 | 14 | 0.020 |
Why?
|
Polymyositis | 1 | 2009 | 7 | 0.020 |
Why?
|
Genetic Linkage | 1 | 2011 | 454 | 0.020 |
Why?
|
Body Mass Index | 1 | 2015 | 1562 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2016 | 804 | 0.020 |
Why?
|
Gene Frequency | 1 | 2011 | 725 | 0.020 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2009 | 26 | 0.020 |
Why?
|
Asbestos | 1 | 2008 | 14 | 0.020 |
Why?
|
Health | 1 | 2009 | 37 | 0.020 |
Why?
|
CD11b Antigen | 1 | 2009 | 36 | 0.020 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2015 | 618 | 0.020 |
Why?
|
DNA Repair | 1 | 2012 | 591 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2015 | 859 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2010 | 174 | 0.020 |
Why?
|
Chemotaxis | 1 | 2008 | 58 | 0.020 |
Why?
|
Carcinogens | 1 | 2008 | 152 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 2008 | 181 | 0.020 |
Why?
|
Neovascularization, Physiologic | 1 | 2009 | 212 | 0.020 |
Why?
|
Quality of Life | 1 | 2017 | 1949 | 0.020 |
Why?
|
Transcription Factor TFIIH | 1 | 2007 | 5 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2010 | 471 | 0.020 |
Why?
|
Blotting, Northern | 1 | 2007 | 262 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2009 | 432 | 0.020 |
Why?
|
Wound Healing | 1 | 2008 | 459 | 0.010 |
Why?
|
Blotting, Western | 1 | 2007 | 1109 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 1532 | 0.010 |
Why?
|
Ethane | 1 | 2001 | 1 | 0.010 |
Why?
|
Pentanes | 1 | 2001 | 1 | 0.010 |
Why?
|
Acetone | 1 | 2001 | 2 | 0.010 |
Why?
|
Sulfur Oxides | 1 | 2001 | 2 | 0.010 |
Why?
|
Butadienes | 1 | 2001 | 19 | 0.010 |
Why?
|
Hydrogen Sulfide | 1 | 2001 | 12 | 0.010 |
Why?
|
Neoplasms | 1 | 2016 | 2800 | 0.010 |
Why?
|
Breath Tests | 1 | 2001 | 178 | 0.010 |
Why?
|